Janux Therapeutics, Inc. JANX

JANX Company Overview

Janux Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on engineered T cell engager therapeutics designed to selectively activate immune responses against tumor cells while reducing systemic toxicity. Janux’s core platform technologies include its proprietary Tumor Activated T Cell Engager (TRACTr) platform and Tumor Activated Immunomodulator (TRACIr) platform, both intended to improve the therapeutic index of immuno-oncology agents by enabling activation primarily within the tumor microenvironment.

The company’s principal revenue drivers currently consist of collaboration and licensing agreements, as Janux remains in the clinical development stage and does not yet market approved commercial products. Janux has focused heavily on prostate cancer and other solid tumors, including programs targeting PSMA and EGFR. The company was founded in 2017 and is headquartered in San Diego, California. Since its formation, Janux has evolved from a platform-focused research organization into a clinical-stage oncology company advancing multiple internally developed therapeutic candidates through human trials.